» Articles » PMID: 17215062

Deficits in Working Memory and Motor Performance in the APP/PS1ki Mouse Model for Alzheimer's Disease

Overview
Journal Neurobiol Aging
Publisher Elsevier
Date 2007 Jan 12
PMID 17215062
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The APP/PS1ki mouse model for Alzheimer's disease (AD) exhibits robust brain and spinal cord axonal degeneration and hippocampal CA1 neuron loss starting at 6 months of age. It expresses human mutant APP751 with the Swedish and London mutations together with two FAD-linked knocked-in mutations (PS1 M233T and PS1 L235P) in the murine PS1 gene. The present report covers a phenotypical analysis of this model using either behavioral tests for working memory and motor performance, as well as an analysis of weight development and body shape. At the age of 6 months, a dramatic, age-dependent change in all of these properties and characteristics was observed, accompanied by a significantly reduced ability to perform working memory and motor tasks. The APP/PS1ki mice were smaller and showed development of a thoracolumbar kyphosis, together with an incremental loss of body weight. While 2-month-old APP/PS1ki mice were inconspicuous in all of these tasks and properties, there is a massive age-related impairment in all tested behavioral paradigms. We have previously reported robust axonal degeneration in brain and spinal cord, as well as abundant hippocampal CA1 neuron loss starting at 6 months of age in the APP/PS1ki mouse model, which coincides with the onset of motor and memory deficits described in the present report.

Citing Articles

Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.

Ortiz-Islas E, Montes P, Rodriguez-Perez C, Ruiz-Sanchez E, Sanchez-Barbosa T, Pichardo-Rojas D Pharmaceutics. 2025; 17(1).

PMID: 39861773 PMC: 11768419. DOI: 10.3390/pharmaceutics17010128.


Effective identification of Alzheimer's disease in mouse models via deep learning and motion analysis.

Liang Y, Sun Z, Chiu K, Hu Y Heliyon. 2024; 10(23):e39353.

PMID: 39687151 PMC: 11647830. DOI: 10.1016/j.heliyon.2024.e39353.


Insights on the Use of Transgenic Mice Models in Alzheimer's Disease Research.

Padua M, Guil-Guerrero J, Prates J, Lopes P Int J Mol Sci. 2024; 25(5).

PMID: 38474051 PMC: 10931675. DOI: 10.3390/ijms25052805.


Assessments of prolonged effects of desflurane and sevoflurane on motor learning deficits in aged App mice.

Niikura R, Miyazaki T, Takase K, Sasaguri H, Saito T, Saido T Mol Brain. 2022; 15(1):32.

PMID: 35387663 PMC: 8988377. DOI: 10.1186/s13041-022-00910-1.


Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy.

Kettwig M, Ternka K, Wendland K, Kruger D, Zampar S, Schob C Nat Commun. 2021; 12(1):6530.

PMID: 34764281 PMC: 8586222. DOI: 10.1038/s41467-021-26880-x.